A diagnosis of DCIS — ductal carcinoma in situ — sits in an awkward place in the breast cancer conversation. The word “carcinoma” makes it sound like cancer; the words “in situ” mean it is contained, not spreading. Both halves of the name are accurate, but they pull in different directions, and patients often leave the appointment with the diagnosis but without a clear sense of what it actually means.

This piece is for patients who have just been told they have DCIS — usually after a screening mammogram or a biopsy of microcalcifications — and want to understand what their pathway is going to look like.

For the strict definition, see the DCIS glossary entry. This piece is the longer-form version: what DCIS is, what it isn’t, how it’s treated, and what the next year typically looks like.

DCIS in plain terms

DCIS is a stage where abnormal cells have formed inside one or more of the milk ducts of the breast, but they have not yet broken through the duct wall into the surrounding tissue. The cells are cancerous in their appearance, but because they are confined to the duct, they have no ability to spread — the way an invasive cancer might.

If DCIS is left untreated, a meaningful proportion of cases would, over time, progress to invasive cancer in the same area. Treating DCIS is essentially preventing that progression. The treatment is therefore about clearing the abnormal area completely so that the chance of progression is reduced as far as possible.

A useful way to think about it: DCIS is a stage 0 finding (it is sometimes called that). It is not yet cancer in the way most people use the word — but it is the stage just before, and the treatment is designed to make sure it does not become that.

How DCIS gets diagnosed

Most DCIS is found through one of two routes:

Screening mammograms picking up clusters of microcalcifications — tiny calcium specks that are characteristic of DCIS. The patient is recalled for further imaging and biopsy.
A biopsy taken for another reason that turns out to also show DCIS — for example, biopsy of a suspicious-looking lump where the surrounding tissue contains DCIS.

DCIS rarely produces a discrete lump that can be felt, and it rarely causes symptoms. This is why screening matters — DCIS is the kind of cancer that screening picks up most reliably, often years before it would have caused any clinical problem.

What the report tells the team

After the biopsy confirms DCIS, the pathology report describes:

Grade — high, intermediate, or low. High-grade DCIS is more likely to progress and is more often associated with invasive cancer hidden alongside it; low-grade DCIS is slower and less aggressive.
Extent — how widely the DCIS appears to spread on the imaging and biopsy.
Receptor status — whether the DCIS cells have the oestrogen receptor, which can inform treatment.
Comedo features — a microscopic feature that, when present, signals more aggressive DCIS.

These features feed into the multidisciplinary team’s recommendation for surgery, follow-up imaging, and (in selected cases) further treatment such as hormone therapy.

How DCIS is treated

The treatment for DCIS is surgery, with the choice between two options similar to invasive cancer:

Lumpectomy plus radiotherapy

For most DCIS, lumpectomy (wide local excision) is the operation of choice — removing the area of DCIS with a clear margin (typically 2 mm) of healthy tissue. This is followed by radiotherapy to the remaining breast tissue to reduce the risk of DCIS or invasive cancer recurring in the same breast.

Radiotherapy after lumpectomy for DCIS reduces local recurrence by approximately half. For some low-risk DCIS in older patients, lumpectomy without radiotherapy is occasionally considered — but for most patients, the radiotherapy is part of the package.

Mastectomy

For more extensive DCIS — covering a wide area of the breast, multifocal, or where the breast is too small for a clean lumpectomy with a good cosmetic result — mastectomy is the alternative. Mastectomy for DCIS is curative in the vast majority of cases (the cure rate is essentially 100% for pure DCIS without any invasive component) and usually does not need radiotherapy afterwards.

For patients having mastectomy for DCIS, immediate reconstruction is usually offered, because there is no requirement for radiotherapy that might compromise the reconstructed breast. The full range of reconstruction options — implant-based, autologous, or aesthetic flat closure — is on the table.

Sentinel lymph node biopsy

DCIS that is confined to the duct cannot spread to lymph nodes, so sentinel lymph node biopsy is not routinely needed for lumpectomy.

For mastectomy, sentinel lymph node biopsy is offered as standard, because once the breast is removed the option to sample the sentinel node is lost — and there is a meaningful chance (around 15—25% in published series) that the final pathology will show an unsuspected invasive component, in which case the lymph node information is needed.

What the pathway looks like over the first year

A typical DCIS pathway for a patient diagnosed via screening:

Weeks 0–2: Recall and biopsy

Recalled from a screening mammogram for further imaging.
Magnification mammogram views and ultrasound.
Biopsy of the suspicious calcifications under mammographic guidance.
Result available within 1–2 weeks.

Weeks 2–4: Surgical consultation

First surgical consultation to discuss the result.
Options laid out: lumpectomy plus radiotherapy, or mastectomy with or without reconstruction.
For some patients, an MRI is added at this stage to clarify the extent of the disease.
Multidisciplinary team review of the case.
Often a second consultation a week or two later to confirm the chosen approach.

Weeks 4–8: Surgery

Lumpectomy as a day-case operation, often with pre-surgical localisation of the calcification area.
Or mastectomy with or without reconstruction — usually with one or two nights in hospital.
Histology of the removed tissue available within 1–2 weeks of surgery.

Weeks 6–10: Result discussion and next-step decision

Final histology — confirms DCIS only, or sometimes finds an unsuspected small invasive component (which changes the treatment plan).
Margin assessment — clear margin or involved margin (which may need a re-excision).
Multidisciplinary team review.
Discussion of any further surgery, hormone therapy, and the radiotherapy plan.

Weeks 12–24: Radiotherapy (for lumpectomy patients)

Radiotherapy starts approximately 6–8 weeks after the most recent surgery.
Course usually 3 weeks (15 daily treatments) — the established UK standard for DCIS. A 1-week schedule (5 treatments) is now standard for invasive breast cancer and is being adopted in some UK centres for DCIS, but uptake varies.
Side effects mostly skin-related — redness, mild discomfort — and settle over weeks after the course.

Weeks 24+: Hormone therapy decision (where applicable)

For ER-positive DCIS, hormone therapy is sometimes offered to reduce the risk of further breast cancer in either breast.
The decision balances modest absolute benefit against years of side effects and is individualised.

Year 1+: Surveillance

Annual mammograms from the time of treatment.
Clinical follow-up at intervals.
For most patients, surveillance is the only ongoing aspect after the first-year pathway is complete.

What can change along the way

A few specific scenarios that change the pathway:

Margin involvement after lumpectomy — needs a re-excision (a second smaller operation through the same incision). See re-excision for involved margins. Happens in approximately 10–25% of cases.
Unsuspected invasive component in the surgical specimen — happens in approximately 10–20% of DCIS cases and changes the pathway: the patient may need sentinel lymph node biopsy at a second operation, and the cancer is then managed as invasive disease (with consideration of chemotherapy, hormone therapy, or HER2-targeted therapy depending on biology). The DCIS-only pathway becomes an invasive-cancer pathway.
Bilateral DCIS — uncommon but possible. Treatment is for each side separately.
Genetic testing — DCIS at a young age (under 50, particularly under 40) prompts consideration of BRCA and other genetic testing, which can change the surveillance and risk-reducing options going forward.

What the long-term picture looks like

The honest framing for DCIS:

Cure rate is essentially 100% for pure DCIS treated with appropriate surgery (and radiotherapy where indicated).
The risk of further DCIS or invasive cancer in the future — in either the operated breast (if conserved) or the other breast — is somewhat raised compared to the general population. Surveillance is the response.
Most patients with DCIS go on to have normal lives with normal breast cancer surveillance and do not develop further breast cancer.

The label “carcinoma” can colour the diagnosis with more weight than the prognostic picture warrants. For pure DCIS, the long-term outlook is excellent.

What to bring to your consultation

The histology report — usually shared with you by the team or available on request.
The imaging report and any images on disc — particularly mammogram views showing the calcifications, plus any MRI if one has been done.
A list of questions — and a person to come with you, if you would like one. A second set of ears helps in a consultation where a lot of information is covered.

If you are weighing up the decision and would like a second opinion on the proposed treatment plan, the practice welcomes those referrals.

What to do next

For a private consultation, contact Sarah or Nadiya, Dr Tsang-Wright’s PAs, at [email protected] or 07785 274 744. For NHS care, the pathway is via your GP or your existing breast unit.

⚠ A new diagnosis of DCIS is not a clinical emergency — there is time to think, to ask, and to make a considered decision about treatment. The decision-making period typically runs over a few weeks rather than days.